Cellectis Presents Epigenetic Editing Platform to Turn Genes Off Without Altering DNA at the ASGCT Annual Meeting
Summary
NEW YORK, April 27, 2026 (GLOBE NEWSWIRE) -- Cellectis (the 'Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using i...
Description
NEW YORK, April 27, 2026 (GLOBE NEWSWIRE) -- Cellectis (the 'Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using i...
Original reporting
AFBytes is a read-only aggregator. Use the original source for full context and complete reporting.
Open original source